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Enzymatically-oxidized phospholipids (eoxPL) form in through regulated highly processes 
by attaching eicosanoids or prostaglandins to phospholipids (PL) in immune cells. These 
comprise structurally diverse families of biomolecules with potent bioactivities, and it is 
becoming increasingly clear that they possess significant immunoregulatory roles in both 
health and disease.  The idea that oxidized PL (oxPL) can even form via enzymatic 
pathways and signal biologically in their own right has only recently been realized.  This new 
paradigm is changing our understanding of eicosanoid, prostaglandin and PL biology in 
health and disease.  eoxPL display emerging roles in cellular events that include ferroptosis, 
apoptosis and blood clotting, and diseases such as arthritis, diabetes and cardiovascular 
disease. They are increasingly being recognized as endogenous bioactive mediators and 
potential targets for drug development.  This review will describe new evidence that is 
placing eoxPLs and their biosynthetic pathways center stage in immunoregulation.  
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Introductory paragraph 
Phospholipid (PL) oxidation occurs widely in inflammatory vascular disease, but for 
many years was considered to involve uncontrolled chemical mechanisms that are 
mediated by free radicals.  However, emerging evidence indicates that enzymatically-
oxidized PL (eoxPL), generated by lipoxygenases (LOX) or cyclooxygenases (COX), are 
abundant biomolecules formed during the acute response to injury in multiple innate 
immune cell types.  eoxPL form via the coupling together of well-known 
eicosanoid/prostaglandin pathways with the Lands’ cycle enzymes, or by direct enzymatic 
oxidation of PL.  New studies suggest eoxPL are important players in early innate immunity, 
particular in promoting blood clotting and defense against infection. Their discovery and 
characterization was enabled by parallel development and application of electrospray 
ionization tandem mass spectrometry (ESI/MS/MS) technology.  While this review focuses 
primarily on eoxPL, we start by introducing the closely-related, non-enzymatically generated 
oxPL. This is to orientate the reader new to this field with the knowledge base that led up to 
the discovery and characterization of eoxPL, as a distinct but related family of bioactive 
lipids.  
 
Enzymatic versus non-enzymatic oxidation of PL.   
eoxPL are considered to be functionally separate from the much larger family of lipids called 
oxidized phospholipids (oxPL), that have been known about since the 1980’s. We note that 
there can be considerable overlap in structures between eoxPL and oxPL families, thus 
determining their specific origin in complex biological samples requires the use of several 
approaches. This includes characterizing their formation in mice lacking eoxPL generating 
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enzymes, determination of enantiomeric composition, and careful use of pharmacological 
inhibitors.   These approaches are expanded on below.    
oxPL form by non-enzymatic oxidation of intact PL where a hydrogen atom is first 
abstracted from a bis(allylic) methylene group in a polyunsaturated FA (PUFA) chain, 
forming a lipid alkyl radical (Figure 1 A). Reactive oxygen species (ROS) generated during 
inflammation (e.g. by cytokine/agonist-activated immune cells) that can directly oxidize lipids 
include hydroxyl radical (•OH), hypochlorite (HOCl), peroxynitrite (ONOO-) and nitrogen 
dioxide (•NO2) (1).  In contrast, eoxPL formation is enzymatic and results in a far more 
restricted set of products formed via highly controlled pathways in innate immune cells. Both 
oxPL and eoxPL generation proceed initially via the same mechanisms involving hydrogen 
abstraction from PUFA, but differ in several key ways that are outlined in detail below.  The 
study of oxPL has preceded the discovery of eoxPL, but there are many parallels in terms of 
biological actions and cellular sources, and it is likely that both pathways are functionally 
linked during chronic inflammatory disease.  Our current view is that eoxPL represent 
physiological mediators of cell signaling that are made during innate immunity to limit 
bleeding and infection. However it is likely that they are also generated at higher levels and 
thus contribute to vascular inflammation.  On the other hand, oxPL generated non-
enzymatically are always considered harmful, contributing to autoimmune and inflammatory 
disease as well as cell death.  
 
Non-enzymatic PL oxidation: chemical mechanisms 
The knowledge that lipids can be non-enzymatically oxidized to oxPL has been appreciated 
for almost two centuries (2). Experiments by Nobel laureate Otto Warburg in the early 1900s 
found that sea urchin egg lipids were targets of iron-catalyzed oxidation (3,4). The 
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requirement for PUFA groups was shown around 80 years ago and the free radical 
mechanisms outlined in the 1940s (5). A major review was compiled in the early 1950s (6).  
  
Following formation of an alkyl radical (initiation), delocalization and oxygen addition occurs 
at diffusion-limited rates to form a hydroperoxyl radical (•OOH) intermediate (Figure 1 B).  
This undergoes various chemical reactions to form a host of oxPL products, including PL-
OOH, by propagation and termination reactions (Table 1, Figure 1 B). A variant of this is the 
direct attack by ozone (O3) on FA groups of PLs that have a single double bond, in a non-
radical mechanism, leading to formation of an ozonide (7). Both ozonides and PL-OOH 
undergo many secondary reactions and multiple oxPL can be formed including terminal 
aldehydes and carboxylic acids. Ozonides form in the protected environment of the lung 
where inspired O3 from pollution encounters PL in the pulmonary surfactant (8).  The 
downstream reactivities/metabolism of PL hydroperoxides (-OOH) are now well 
characterised along with the diversity of products derived from free radical (chemical) auto-
oxidation, and the reader is guided to relevant references (9-11).  
 
An important feature of non-enzymatic oxidation to form oxPL is that products form without 
stereochemical control, that are racemic and regioisomeric.  This distinguishes oxPL from 
eoxPL, where enzymatic mechanisms control of oxygen insertion yielding specific 
enantiomers.  Analysis of these products using chiral chromatography can thus help to 
distinguish oxPL from eoxPL.   
 
The generation of oxPL in vascular disease 
Research into vascular formation of oxPL started in the 1980s-90s, led by Berliner, 
Leitinger, Salomon and colleagues (reviewed in (11)).  Early work showed that oxPL are 
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present in atherosclerotic plaque, and this stimulated elucidation of vascular oxPL 
structures, and their potential bioactivities(12-15). The major oxPL class in vascular lesions 
was reported as phosphatidylcholine (PC), although it is not clear whether this was because 
other oxPL classes were not looked for, or were present in lower amounts.  At that time, 
synthetic oxPC was generated in vitro via air/metal-catalyzed oxidation and then applied to 
cellular or in vivo systems, in which pleiotropic bioactivities relevant to inflammation were 
demonstrated(11). This led to the idea that oxPL is formed in excess and promotes 
inflammation, driving atherosclerotic vascular disease.  This was further supported by 
findings from Witztum and Hörkko that mice with atherosclerosis generated oxPL-specific 
IgM antibodies from the innate immune system, whose levels had an inverse relationship 
with disease, and provided vascular protection through mopping up these lipids(16-19). 
However, synthetic oxPL is a complex mixture of hundreds of products.  When generated by 
different labs using unstandardized conditions there was inconsistency in terms of chemical 
composition, which usually was not defined. This led to oxPL preparations showing opposite 
biological actions in the same assay systems (11). Later, in the 90’s, researchers began to 
separate the components of synthetic air-oxidized oxPL.  A number of forms, including 
truncated lipids where the PUFA has been oxidatively shortened were purified and studied 
in isolation(20-23). These, including 1-palmitoyl-2-(5-oxovaleryl)-sn-glycero-3-PC (POVPC), 
1-palmitoyl-2-epoxyisoprostane-sn-glycero-3-PC (PEIPC), 1-palmitoyl-2-glutaroyl-sn-
glycero-3-PC (PGPC) and others were also detected in human and murine atheroma 
lesions(12-15).  To date there is only an incomplete understanding as to how these form in 
vivo.  While generally assumed to be generated non-enzymatically, we could speculate that 
enzymes such as LOXs or COXs might catalyze the initial oxidation forming lipid 
hydroperoxidesbo.  If antioxidants are depleted, then these could be non-enzymatically 
oxidized to lipid radicals which would then propagate leading to racemic downstream oxPL 
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formation. However, the idea that enzymatic initiation of oxidation could lead to downstream 
oxPL formation is yet to be tested using biological models, such as Alox-deficient mice.  
 
Regardless of how oxidation is initiated, the initial product of PL oxidation will always be a 
PL-OOH, which is chemically reactive and can decompose to a plethora of products 
including chain shortened PL species, such as POVPC. Reduction to the chemically less 
reactive PL hydroxide (-OH) is catalyzed by a specific PL-OOH reductase, glutathione 
reductase 4 (GPX4) which limits chemical reactivity of the PL-OOH(24).  Direct oxidation of 
cardiolipins containing LA is also known to take place in the mitochondria by cytochrome c 
leading to the formation of cardiolipin-OOH(25). 
 
Enzymatic oxidation of PL forms eoxPL. 
In contrast to uncontrolled non-enzymatic oxidation described above, we now know that the 
cellular generation of eoxPL is a highly controlled process, mediated by redox active 
proteins (enzymes). As for oxPL formation, molecular oxygen is inserted into a PUFA group 
to generate a lipid-OOH, however, a far more restricted set of structures is formed, including 
specific regio- and stereoisomers, thus these are termed eoxPL (26-29).  The overall 
mechanism is as in Figure 1, except that the removal of the hydrogen atom is carried out by 
iron in a metalloenzyme (LOX), or by a tyrosyl radical (COX), and the site of oxygen 
insertion is controlled due to steric positioning within the active site. Several cell types of the 
innate immune system generate eoxPL, with the enzyme isoforms involved being cell-type 
specific(29). 
 
There are two distinct mechanisms for eoxPL formation, direct oxidation of an intact PL, or 
indirect oxidation where a preformed oxidized FA (oxFA) is inserted into a lysoPL via the 
	 7	
enzymes of the Lands remodeling cycle, and these are described below in more detail 
(Figure 2 A,B).  
 
Direct enzymatic oxidation of PL is catalyzed by the leukocyte 15-lipoxygenase (LOX) 
(human) or 12/15-LOX (murine) (both from the ALOX15 gene) (Figure 2 A) (27,30).  This is 
highly expressed in human eosinophils and IL-4/IL-13-treated monocytes, and generates 
free 15-hydroperoxyeicosatetraenoic acid (15-HpETE), which is rapidly reduced by cellular 
GPXs, to the more stable 15-hydroxyeicosatetraenoic acid (15-HETE)(31,32). High levels of 
esterified 15-HETE from 15-LOX were first observed by Kühn in human eosinophils 
following stimulation by calcium ionophore(33).  Later, human monocytes were shown to 
have 15-HETE esterified to PL, specifically phosphatidylethanolamine (PE)(27).  Similarly, 
in mice, leukocytes including eosinophils and resident peritoneal macrophages generate 12-
HETE-PEs via Alox15(30).  Unlike indirect oxidation (described below), eoxPL from 
ALOX15 are present in resting cells, and their formation doesn’t strictly require agonist 
activation.  This suggests they play homeostatic roles in innate immunity.  Direct oxidation 
of PE to form HETE-PE was demonstrated in both mouse and human 
monocyte/macrophages using a stable isotope dilution MS approach, monitoring for 18O 
incorporation following cell activation in 18O-H2O buffer (27,30). Lack of incorporation is 
consistent with direct oxidation, since there is no cycle of hydrolysis and re-esterification.  
 
Indirect enzymatic oxidation describes formation of eoxPL via the Lands’ pathway (Figure 2 
B).  The definitive step of this enzymatic reaction involves a CoA ester of an oxFA  formed 
by a long-chain fatty acyl CoA synthetase (ACSL). This is then esterified onto a lysoPL 
acceptor, by lysoPL acyl transferases (LPAT), which have also been termed membrane 
bound O-acyl transferases (MBOAT).  Recently, the complete cycle of eoxPL formation was 
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revealed as a rapid and co-ordinated process that occurs in several immune cell 
types(26,28).  This comprises (i) PL hydrolysis by PLA2 releasing FA, (ii) formation of oxFA 
(typically an eicosanoid or prostaglandin) by FA oxidation catalyzed by COX or LOX, then 
(iii) re-esterification of the oxylipin to a lysoPL to form eoxPL by FACL+LPAT.  This occurs 
in platelets and neutrophils, where FA oxidation is primarily catalyzed by 12-LOX (ALOX12) 
or 5-LOX (ALOX5) respectively(10,28). In platelets, the most quantitatively abundant eoxPL 
comprise 12-HETE attached to PE or PC.  This is not surprising since AA represents the 
most abundant long-chain PUFA in immune cell PL membranes, followed by linoleic acid 
(LA) and docosahexanoic acid (DHA).  Also, PE and PC are the most abundant PL classes 
in the plasma membrane, and include both acyl and plasmalogen forms. 14-
hydroxydocosahexanoic (HDOHE) acid-PEs are also detected in platelets, arising from DHA 
oxidation by 12-LOX(34).  Similarly, fMLP-stimulated neutrophils generate primarily 5-
HETE-PE/PCs via the action of 5-LOX on AA, followed by esterification of 5-HETE into 
lysoPL(26).  A requirement for hydrolysis and re-acylation was confirmed in both platelets 
and neutrophils using 18O-H2O stable isotope dilution MS, and/or thimerosal to block fatty 
acyl esterification (26,28).   
 
Our studies show that ALOX15 mediates direct PL oxidation, while ALOX5 and ALOX12 
generate HETE-PEs via Land’s cycle remodeling in innate immune cells.  This is fully in line 
with what has been known regarding the substrate preferences of these proteins, based on 
older in vitro studies using recombinant or purified enzymes for many years. Unlike other 
LOX isoforms, the purified 15-LOX1/12/15-LOX was well known to be capable of direct 
oxidation of PL substrates(35,36).  
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Whether reduction of the HpETE to HETE by GPX occurs before or after esterification is not 
known, and in both platelets and monocytes, both HpETE- and HETE-PEs have been 
detected, arising from LOX turnover(27,28). Approximately a third of all the 12-HETE 
generated by human platelets is esterified into PC and PE, on the same timescale as 
formation of free 12-HETE(28).  Thus, eoxPL form rapidly on cellular activation and are 
abundant lipids, present at picomole to nanomole levels. This temporal generation suggests 
that the synthetic enzymes are co-located and working co-operatively.  In support, 
exogenously added stable-isotope labeled 12-HETE is not incorporated into PE in thrombin-
stimulated platelets during endogenous 12-HETE-PE formation(28). This indicates a new 
paradigm for the Lands’ cycle, generating immune bioactive eoxPL lipids in circulating 
human and murine innate blood cells via remodeling of their biomembranes, as an acute 
response to stimulation.    
 
A second way in which eoxPL may form via indirect oxidation involves transcellular uptake 
of precursor oxylipins (generated in a different cell type), followed by their esterification.  
Early studies from Serhan and others in the ‘90s focused on this route, adding exogenous 
oxylipins to cells and measuring their esterification into PLs. For example, exogeous 15-
HETE (a monocyte/eosinophil LOX product) is incorporated into PI in neutrophils, and then 
subsequently released on fMLP activation of phospholipases(37).  However, rates of uptake 
and esterification of exogenous substrate take place on relatively long timescales (several 
minutes - hrs) and whether this occurs in vivo is unknown.  The phenomenon of oxylipin 
incorporation into lysoPLs has also been observed for epoxyeicosatetraenoic acid (EETs) 
generated by cytochrome P450 enzymes (38,39).  In that example, a potential role for EET-
PLs in altering membrane microdomain properties or acting as a releasable pool of oxylipins 
was proposed (38).  Esterification of 14,15-EET occurs in mastocytoma cells with half 
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maximal incorporation around 30 min (40).  Thus it is on a similar timescale to transcellular 
oxylipin incorporation described above, but considerably slower than endogenous HETE-PE 
generation in immune cells.  It has been suggested that PL incorporation of oxylipins 
through this transcellular uptake route leads to formation of a pool of “stored” eicosanoids 
that can be released later.  However, even if this is the case, eoxPL such as HETE-PEs 
possess immunoreactive bioactivities in their own right that require the oxylipin to remain PL 
esterified.  These are described in detail later.  
 
In addition to ALOX12, platelets can also generate eoxPL via COX-1, specifically PGE2-PE 
and PGD2-PE (41,42).  However despite the quantitative abundance of thromoboxane-B2 
(TXB2), attachment of this eicosanoid to PLs has never been detected. This suggests that 
esterification pathways may show oxylipin selectivity, in line with recent studies from Klett 
using purified ACSLs (43).  To date, studies examining cellular COX-2 generation of eoxPL 
have not been undertaken, but this could represent a source of esterified prostaglandins 
during chronic inflammation.  
 
Up to 2016, a relatively small number of eoxPL molecular species had been determined in 
innate immune cells, typically 4-6 molecular species per cell type.  However, human 
platelets were recently shown to rapidly form > 100 unique eoxPL structures, from ALOX12 
and/or COX-1 on thrombin activation(44).  The most abundant are PEs, however PC forms 
are also prevalent, and rarer HETE-PI forms were recently discovered(44,45).  As well as 
AA or DHA-derived eoxPL described earlier, -OH forms of 22:4, 22:5, 20:3 and 20:5 are 
formed, but at lower amounts. Rarer multiply oxidized AA species, containing either >2 - 3 
oxygens are also generated(44).  These lower abundance eoxPLs have so far only been 
measured in platelets but may also be formed in other cells expressing high levels of LOXs 
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or COXs during inflammation.  Many eoxPL are not fully structurally elucidated yet, with 
position of oxidation sites still unassigned.  Several tandem mass spectra are available, 
derived from platelet eoxPL, for future characterization(44).   
 
Indirect enzymatic oxidation requires agonist activation of innate immune cells, achieved in 
platelets or neutrophils by thrombin, collagen or fMLP.  In platelets, thrombin activates 
protease activated receptors (PAR)1 and PAR4, while fMLP activates FPR1 in neutrophils.  
This then leads to downstream calcium mobilization and phospholipase activation, both 
required for eoxPL generation(26,28).  Pharmacological inhibitors have suggested 
involvement of additional signaling pathways in platelets and neutrophils, including protein 
kinase C, src tyrosine kinases, phospholipase C, MAP Kinases, cPLA2, sPLA2 and 5-LOX 
activating protein (FLAP), although formal studies in genetically-deficient mice have not yet 
been undertaken(7,37).  These studies reinforce the idea that eoxPL generation is a 
regulated physiological process of importance to innate immunity.   
 
Approaches to distinguish eoxPL from oxPL in cellular and tissue systems 
There is considerable structural overlap between oxPL and eoxPL species.  Furthermore, 
whether oxPL can be formed via decomposition of eoxPL (e.g. metal-dependent 
decomposition of LOX derived HpETE-PEs) is still unclear. Thus, when measuring these 
lipids, it can be challenging to determine their precise biochemical origin.  Furthermore, the 
biosynthetic pathways for truncated oxPL detected in plasma are unknown, and there is 
ongoing debate regarding the origin of lipid oxidation products that drive ferroptosis. Despite 
this, several approaches can help delineate the origin of oxidized PL as follows: 
1. Tissue or cells lacking Alox through genetic deletion or pharmacological inhibition.  
Mice lacking several Alox isoforms are available, and both Alox12-/- and Alox15-/- 
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mice have been shown to be unable to generate platelet or macrophage HETE-PLs, 
respectively (30,46).   Pharmacological inhibitors for platelet 12-LOX or leukocyte 15-
LOX (12/15-LOX) are not generally specific and most are either antioxidants or lipid 
analogs, and thus will also inhibit oxPL formation.  The exception to this is MK886, an 
inhibitor of 5-LOX activating protein (FLAP) which as used to implicate 5-LOX in 
neutrophil HETE-PL formation (26).  Pharmacological inhibitors for COX including 
aspirin, indomethacin or COX isomer specific inhibitors such as celecoxib can also 
be used to implicate this pathway in esterified PG formation(41).  
2. Reverse phase and chiral chromatography to confirm regio- and enantiomeric 
specificity. EoxPL formation involves regio- and stereo-specific oxygen insertion by 
enzymes.  For example, platelets generate primarily 12SHETE-PL isoforms(28).  
Thus, a predominant isomeric composition reflective of enzymatic activity can 
distinguish oxPL from eoxPL.  MS/MS fragmentation (monitoring the intact HETE 
fragment, versus internal daughter ions that arise from HETE fragmentation on 
collision-induced-dissociation), or alternatively saponification of purified 
phospholipids followed by HPLC-UV detection of HETE positional isomers can first 
determine regio-specificity.  Following this, free acid HETEs obtained by 
saponification can be subject to chiral chromatography to determine enantiomeric 
composition. These approaches have been used for platelets, neutrophils, 
monocytes and murine macrophages to confirm the involvement of LOX isoforms in 
eoxPL formation  (26-28,30) 
 
A final point relates to the relative amounts/importance of eoxPL vs oxPL in specific disease 
settings, and ascribing biological roles in vivo. Currently, little quantitative information exists 
on this issue, to some extent due to lack of authentic standards for measuring their amounts 
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in tissues. Truncated oxPCs are available from Avanti Polar Lipids, and we have 
synthesized and purified HETE-PE and –PC positional isomers generated by either 
soybean LOX or air oxidation (47). Using these, isolated platelets and neutrophils were 
found to generate ng amounts of HETE-PEs exclusively via enzymatic mechanisms, while 
truncated oxPL were not detected to form (26-28,30).  Indeed, platelets esterify 
approximately 30% of newly synthesized 12-HETE into PL pools during the same timescale 
as free 12-HETE synthesis.  This provides an example where eoxPL predominate, however 
we suspect that in chronic inflammation, where reactive oxygen and nitrogen species are 
generated, the situation may change over time.  In support, a previous study comparing 
enantiomeric specificity of esterified HODEs in human atheroma lesions showed a 
predominance of the 13S form in early lesions, but a racemic mixture in more progressed 
disease (48).  For testing involvement of lipids in disease, Alox-deficient mice are a suitable 
model, however these enzymes make many oxylipins making ascribing function to specific 
lipids challenging.  To that end we recently administered HETE-PLs to mice, either locally 
into the tail, or systemically via tail vein and found them to be well tolerated, with acute 
effects on hemostasis and thrombosis being seen in line with their proposed pro-coagulant 
actions (46,49). 
 
Functions of eoxPL during innate immunity. 
Although LOX isoforms are different gene products, separated in evolution with distinct 
cellular expression profiles, the generation of similar eoxPL classes by different innate 
immune cells (particularly HETE-PLs), suggests overlapping functions.  HETE-PLs are 
generated by immune cells under conditions relevant to “response to injury” or acute 
trauma, such as following challenge by haemostatic or infectious agents(29).  This suggests 
a protective role in this context, where prevention of bleeding or infection is a primary goal. 
	 14	
Conversely, their generation in excess may promote vascular inflammation, in particular 
arterial thrombosis in atherosclerotic disease, or venous thrombosis(46,50). Of relevance to 
this, a large literature on the bioactions of non-enzymatically-generated oxPL (including 
structures that we now know are also eoxPL, such as HETE-PE) exists showing they can be 
either pro- or anti-inflammatory depending on the context(11,51).  However, in many studies 
on oxPL, the lipids were derived by air/chemical oxidation and biological actions cannot be 
attributed to any specific molecules.  An exception to this is POVPC, which is recognized by 
the CD36 scavenger receptor, and thus considered a damage-associated molecular pattern 
(DAMP) molecule(52).  
 
A key difference between eoxPL and their prostaglandin/eicosanoid precursors is that they 
are not secreted but due to their limited solubility in water and lipophilicity, they remain cell-
associated, residing within membranes.  This phenomenon has been shown for HETE-PEs 
in several cell types (26-28). Free acid eicosanoids/prostaglandins mediate their potent 
bioactivities through binding and activating G-protein coupled receptor signaling at sub 
picomolar concentrations, however current evidence indicates that HETE-PL mainly exert 
their effects through ow affinity interactions with proteins, and/or altering membrane 
electronegativity, leading to changes in how proteins interact with membranes (e.g. in blood 
clotting).  The lipid whisker model for oxPL signaling, which proposes that more electrophilic 
oxidized fatty acid moieties protrude into the extracellular space, provides some hints 
regarding how HETE-PLs might signal(53). Introduction of polar character into the 
membrane has significant potential to change the local environment for integral membrane 
proteins and receptors. This may explain many observed effects of the lipids, on diverse 
systems including coagulation.  Thus, our current view is that eoxPL are unlikely to mediate 
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high affinity receptor-ligand interactions, in a manner similar to eicosanoids or 
prostaglandins.  
 
Innate immune cells undergo significant changes to their membrane structure on agonist 
activation, including spreading, adhesion, chemotaxis, microvesicle formation, 
degranulation, etc.  How plasma membranes containing HETE-PLs may influence these 
phenomena is currently not understood.  Hints come from studies on chemical oxidation of 
membranes.  For example, mixtures of oxPL generated through chemical or air oxidation 
induce flattening and thinning of artificial membranes, and increase water permeabilization, 
in part due to the hydrophilic nature of the sn2 oxidized lipid (54). Specifically, the 
introduction of a polar group may cause the acyl chain to partially bend, narrowing the 
hydrophobic core of the membrane (54). Also, high concentrations (mg/ml) of purified 15-
LOX cause pore formation in purified organelle membranes, through lipid peroxidation, and 
its overexpression in non-erythroid cells is associated with mitochondrial membrane 
collapse (55). Thus, endogenous LOX in immune cells could mediate profound changes to 
the plasma membrane on agonist activation (possibly via generation of HETE-PLs).  
 
Alternatively eoxPL can act as low-affinity ligands for nuclear receptors, such as PPARγ or 
regulate signaling by Toll like receptors via their structural similarity with bacterial lipids such 
as lipopolysaccharide (LPS)(30,56).  These actions will be summarized below.  
 
(i) Haemostasis and thrombosis 
Aminophospholipids (aPL), specifically native phosphatidylserine (PS) and PE are essential 
for effective blood clotting. Normally, PS and PE are retained on the inner leaflet of the 
plasma membrane, however when immune cells are activated, they are externalized via 
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scramblase activity(57,58). Then, negatively-charged Gla domains of plasma coagulation 
factors associate with PS and PE on the activated platelet membrane surface via calcium 
ion binding.  Thus, coagulation factors come together on a PL surface, allowing them to 
effectively interact, facilitating proteolytic cleavage and ultimately thrombin 
generation(57,58). This assembly of distinct coagulation factors at the platelet surface then 
promotes fibrin polymerization and clotting, providing a backbone for the stabilization of a 
platelet-rich thrombus that rapidly forms upon aggregation of these cells in response to 
vascular injury. 
 
Several recent studies support an essential role for eoxPL in promoting PS-dependent 
coagulation, in vitro and in vivo (46,49,50). Specifically, HETE-PE or HETE-PCs enhance 
the ability of PS to interact with multiple clotting factors, increasing rates of thrombin 
generation and ultimately promoting haemostasis (Figure 3) (46,49,50).  Mice genetically 
lacking HETE-PLs (either Alox15 or Alox12 deficient) bleed longer on challenge, suggesting 
that endogenous eoxPL support haemostasis in vivo(46,50).  Injection of HETE-PEs 
restores in vivo hemostasis in mice, evidenced by elevated thrombin-anti-thrombin (TAT) 
complexes, and rescues the bleeding phenotype(46).  The mechanisms have been 
extensively investigated. Purified HETE-PE or HETE-PCs increase thrombin generation in 
human plasma, and molecular dynamics simulations show that the –OH group of the HETE 
resides close to the polar external face of the membrane, interacting with calcium and 
pushing PL headgroups apart(46,49).  HETE-PLs promote calcium binding to membrane 
surfaces, and liposomes containing these lipids are smaller and show greater curvature, 
also increasing accessibility of charged PS headgroups to coagulation factors(49).    
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12-HETE-PEs form primarily at the inner leaflet of the activated platelet membrane, with a 
proportion externalizing to the outer face(28).  12-HETE-PCs should be found on the 
outside of the lipid bilayer, since this is where PC primarily is located.  Externalization of 
HETE-PE has been detected in platelets and macrophages. Here, exposure of eoxPL 
parallels that of PS, but occurs independent of apoptosis via incompletely defined 
pathways(59). In platelets, the protein TMEM16F contributes to non-apoptotic PS exposure 
and is likely involved in the exposure of eoxPL in these and other cells(59). Notably, 
platelets are not the only cell type that utilizes HETE-PLs to initiate coagulation.  Eosinophils 
also play a key role in this process, with recent studies showing that both human and 
murine eosinophils generate HETE-PEs, and that ALOX15-deficient eosinophils poorly 
support tissue factor-dependent thrombin generation in vitro(50).  However, unlike platelets, 
eosinophil HETE-PE levels do not appear to increase on cell activation (with ADP).  Instead, 
their procoagulant activity relies on PS externalization being stimulated by ADP, with the 
ability of PS to support coagulation being significantly enhanced by ALOX15-derived eoxPL 
already basally present in the cell membrane(50).   
 
Recent evidence indicates that HETE-PLs are involved in the pathogenesis of both arterial 
and venous thrombosis. For example, they are found elevated in circulating leukocytes and 
platelets from patients with antiphospholipid syndrome (human venous thrombosis), where 
they also stimulate an immune response(46). During stroke and myocardial infarction, 
ALOX12-expressing platelets form the major cell type within the initial thrombi and directly 
attach to sites of vascular injury. ALOX15-expresing eosinophils, in turn, are recruited to the 
initial platelet-rich thrombus where they seem to essentially contribute to eoxPL generation 
as well as to thrombin generation and fibrin polymerization(50). Histological analysis of both 
murine and human thrombi shows both eosinophils and eosinophil activation markers are 
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elevated in patients with thombotic diseases such as stroke and myocardial infarction(50). 
Similarly, absence of ALOX12, ALOX15 or of eosinophils results in partial protection from 
venous thrombus formation in mouse models(46,50).  
 
Conversely, the pro-coagulant action of HETE-PLs could potentially be harnessed 
therapeutically in conditions of hemostatic failure, such as trauma/surgical injury or bleeding 
disorders. We found that HETE-PLs can completely prevent bleeding in mice genetically 
deficient in Factor VIII (FVIII), and can improve thrombin generation in human plasma 
lacking either FVIII, IX or X(49).   
 
(ii) Leukocyte antibacterial and inflammation regulatory actions of eoxPL 
Circulating blood leukocytes are the first responders to injury, including neutrophils which 
engulf bacteria, and monocytes that differentiate into macrophages to participate in 
resolution of damage/wound healing.  Both these cell types generate HETE-PLs that show 
bioactivities consistent with supporting innate immunity and defense against infection.  
Neutrophils generate 5-HETE-PLs via ALOX5, on acute activation by bacteria or their 
products such as fMLP and LPS(26).  These are found in human bacterial infection in vivo, 
particularly Gram+ve, and in vitro they enhance superoxide and IL-8 generation, while 
suppressing neutrophil-extracellular trap formation(8). Macrophages/monocytes generate 
eoxPL via ALOX15, specifically four HETE-PEs and also their reduced carbonyl-containing 
analogs, ketoeicosatetraenoic acid (KETE)-PEs formed by prostaglandin dehydrogenase 
(PGDH) reduction of HETE-PEs(27,30,56). We found that HETE-PEs dampen cytokine 
generation in monocytes by inhibiting LPS-activation of TLR4(30).  However, HETE-PEs 
can also act as TLR4 agonists due to their structural similarity with LPS(60).  It is likely that 
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their dual action results from either (i) direct weak activation of TLR4, or (ii) acting as 
competitive inhibitors of binding of the far more potent activator, LPS.  
 
 
Role of eoxPL/LOXs in inflammatory and immune disease. 
Multiple studies show that LOXs, in particular ALOX15 are pro-inflammatory in murine 
models, including atherosclerosis, diabetes, hypertension and arthritis.  However LOXs can 
generate many oxylipins, including HETEs, HODEs, leukotrienes, hepoxilins, lipoxins, etc, 
as well as eoxPL and in most cases, the specific lipids mediating their inflammatory actions 
are not clear.  Below we provide a summary of murine and human studies in this area, that 
strongly suggest an involvement for eoxPL in diverse disease pathologies.  
 
(i) Immune mediated inflammatory disease and eoxPL 
Multiple forms of oxPL/eoxPL molecular species are detected in both early and late 
atheroma, however, as described earlier, it is still unclear which of these derive from non-
enzymatic oxidation or whether LOXs/COXs initiate their formation. In support of a potential 
role for LOXs, macrophages within plaque express high levels of ALOX15 (61,62). Genetic 
absence of ALOX15 reduces oxidization of LDL and ameliorates formation of atherosclerotic 
lesions in several mouse models(63-65).  Non-enzymatically generated oxPLs such as 
POVPC and PEIPC trigger activation of vascular endothelial cells and smooth muscle cells 
in vitro and in vivo, stimulating expression of chemokines and adhesion molecules(66-68).  
Similarly, these events can be also triggered by artificial overexpression of ALOX15 in 
endothelial cells(69). In vitro generated POVPC and PGPC also promote monocyte 
adhesion and leukocyte transmigration (15). Macrophages directly activated by a crude 
mixture of air oxidized PC (which will undoubtedly contain HETE-PCs) substantially change 
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their phenotype, a phenomenon that is also seen in atherosclerotic plaques in vivo (70). 
These studies are consistent with a role of both eoxPL and oxPL in driving inflammatory 
vascular disease in vivo.   
 
ALOX15-derived HETE-PLs are upregulated in monocytes by incubation with type 2 
cytokines, IL4/IL14, and are detected in type 2 inflammation, including mouse models of 
lung allergy (30) Also ALOX15 expression and HETE-PE are elevated in bronchial epithelial 
cells and observed in infiltrating alternatively-activated macrophages (AAM) and 
eosinophils(27,50). During asthma ALOX15 has been implicated in mucus hypersecretion 
via HETE-PE generation and can contribute to airway epithelial injury (71).  
 
(ii) Role of eoxPL in immune tolerance 
Recent studies uncovered an essential role for ALOX15 and HETE-PEs during controlling 
self-tolerance and resolution of inflammation(72-76). Both enzyme expression and levels of 
HETE-PLs peak during resolution coinciding with appearance of eosinophils and AAMs and 
the re-emergence of tissue resident macrophages (30,76). During resolution, ALOX15 
modulates the cytokine response of infiltrating immune cells and contributes to the non-
immunogenic removal of apoptotic cells by ALOX15-expressing tissue-resident 
macrophages (75,77). In this, 12-HETE-PEs are expressed on the surface of resident 
macrophages where they facilitate clearance of apoptotic cells by this macrophage 
subset(75). However, they appear to conversely interfere with the uptake of apoptotic cells 
by immune-competent monocyte-derived macrophages and dendritic cells during 
inflammation(75). Generation of HETE-PEs thus facilitates a “silent waste-disposal” that is 
executed by tissue resident macrophages ensuring a non-immunogenic clearance of 
apoptotic cell-derived autoantigens, and enabling maintenance of self-tolerance during 
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inflammation (Figure 4) (75). Generation of ALOX15-derived HETE-PC and HpETE-PC by 
dendritic cells in turn seems to increase their activation threshold and helps these cells 
maintain an immature phenotype during steady state (72,78).  This partially involves 
activation of the redox-sensitive transcription factor Nrf2(72,79). Absence or inhibition of 
Alox15 results in spontaneous activation and maturation of dendritic cells(72). Immune-
regulatory features of ALOX15-derived HETE-PLs may explain why Alox15-deficient 
animals show spontaneous autoimmunity including the presence of anti-nuclear antibodies, 
and exacerbated disease in models of systemic lupus erythematodes, multiple sclerosis, 
rheumatoid arthritis and systemic sclerosis(72,75,80-82).   
 
(iii) The pro- vs anti-inflammatory actions of eoxPL are context dependent. 
It has to be emphasized that mechanisms underlying the pro-inflammatory as well as the 
anti-inflammatory and immune modulatory properties of oxPL and eoxPL are still 
incompletely understood and likely dependent on cell type, site of generation as well as on 
type and amount of the individual phospholipid species, including the repertoire of FA side 
chains. Studies addressing the biological properties of non-enzymatically oxPL, primarily 
oxPC derivatives, show that these lipids share common immune-modulatory features of 
eoxPL, usually HETE-PLs. Low concentrations of oxPC/eoxPL are anti-inflammatory, 
blocking LPS activation and maturation of dendritic cells, macrophages and endothelial cells 
(30,72,78,79,83,84). Proposed anti-inflammatory mechanisms involve blockade of cell-
surface and soluble pattern recognition receptors (PRRs) such as TLR4, CD14 and LBP as 
well as activation of Nrf2, exerting potent anti-inflammatory activity (72,79,83,84). High 
amounts of oxPC or increased/overwhelming production of eoxPLs, on the other hand, can 
result in the inflammatory activation of the same cell types. Here, a shift from a blockade to 
an activation of TLRs as well as binding to additional PRRs such as CD36 suggestive of 
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partial-agonistic properties on TLR and PRR signaling has been observed(60,85,86). Also 
binding to G-Protein-coupled receptors such as the PAF receptor by POVPC has been 
described, although given the requirement for PAF receptor activating lipids to be 
oxidatively truncated, a role for cell-generated HETE-PLs is unlikely in this case (87). It was 
recently shown that high concentrations of air-oxidized PC mixtures trigger the intracellular 
inflammasome pathway leading to activation of caspase 11 and release of IL-1β (88). These 
findings suggest that biological properties of both eoxPL and non-enzymatically generated 
oxPLs are highly dose- and context-dependent and that generation of eoxPLs needs to be 
tightly balanced to maintain homeostasis.  We note that air-oxidized PC (oxPAPC) which 
contains 100s -1,000s of products is still often used for biological studies, including some 
cited above.  Unfortunately, using these mixtures, it is not only unclear which specific lipid is 
mediating the biological effect, but also the effective concentrations of active lipids and their 
biological relevance are also difficult to delineate.    
 
Emerging roles for eoxPL in ferroptosis and pathogen biology 
Ferroptosis is a regulated form of necrosis, implicated in diverse processes including cell 
death during tissue turnover, cancer cell death and aggravation of tissue injury(89). It was 
recently found that ferroptosis involves the rapid and massive generation of eoxPL (mostly 
PE, including oxidized adrenic acid containing forms) by PL peroxidation in an iron- 
dependent manner(90-92). The presence of PL with long polyunsaturated ω6 fatty acids 
within cellular membranes is a prerequisite for eoxPL formation during ferroptosis, and is in 
turn dependent on enzymes involved in PL synthesis such as acyl-CoA synthetase long-
chain family member 4 (ACSL4)(90). Onset of lipid peroxidation during ferroptosis involves 
insufficiency and shutdown of anti-oxidative enzymes such as GPX4 as well as LOX-
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mediated peroxidation that at least partially involves ALOX15 (Figure 5). Insights into the 
physiological and pathological implications of this type of cell death are currently emerging.   
 
While most of our knowledge on eoxPL biology comes from their generation in murine or 
human systems, pathogens such as Pseudomonas aeruginosa and Toxoplasma gondii 
express enzymes with 15-LOX activity.  These have been most likely acquired by horizontal 
gene transfer by these organisms as they display a high sequence homology to mammalian 
ALOX15 (93,94). These LOXs were recently shown to generate HETE-PLs and other 
eoxPLs and might contribute to the pathogenicity of these pathogens e.g. by enabling 
immune evasion or induction of hemolysis or even ferroptosis, but this is not yet 
known(95,96).  
 
The analysis of oxidized phospholipids (oxPL) using MS, historical context. 
The ability to analyze oxPL/eoxPL as chemical entities emerged with the advent of modern 
biological MS. The first report of molecular ions generated from intact PC employed field 
desorption ionization(97). However, it was not until fast atom bombardment ionization (FAB) 
was introduced by Barber in 1981 that intact PC could be studied widely (98,99). FAB was 
developed in parallel with tandem MS, and represents the most widely used method of PL 
analysis today. With this, collisional activation (via multiple collisions with a neutral gas) is 
used to initiate carbon-carbon bond cleavage, forming product (daughter) ions that can be 
separately analyzed(100). This is also called collision-induced dissociation (CID). The 
terminal sector of tandem instruments then enabled determination of the mass-to-charge 
ratio (m/z) to be measured, providing the molecular mass of the PL.  Another important 
advance was the development of high-performance tandem MS instruments that enabled 
measurement of precursor and product ions with a high mass accuracy, enabling calculation 
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of exact elemental composition (high resolution MS). Understanding the gas phase ion 
chemistry that occurs as a result of CID permitted one to propose structures consistent with 
elemental composition of fatty acid (FA), PL and oxPL ions.  A detailed knowledge of PL 
and eicosanoid/prostaglandin gas phase chemistry has developed over the past few 
decades as a result of studying the MS behavior of known lipids(101,102). Thus it is now 
possible to characterise not only the structures, but also the mechanisms of lipid oxidation 
by either enzymatic or non-enzymatic pathways in cell and tissue samples using MS 
analysis(103). 
 
The ionization methods most often used for FA, eicosanoid/prostaglandin, PL and 
oxPL/eoxPL analysis are electrospray ionization (ESI), discovered by Nobel laureate John 
Fenn, and matrix assisted laser desorption ionization (MALDI)(104). These were both 
developed in the middle 1980s. Ions generated by MALDI or ESI undergo very similar CID 
decomposition mechanisms. Thus understanding the ion chemistry of the oxPL is relevant 
to observations made by either method. ESI is widely used due to its ease of 
implementation, as well as the breadth of molecules that can be analyzed including 
nonvolatile molecules such as PL and its various oxidation products. In addition, with ESI it 
is easy to interface the mass spectrometer to the effluent of a liquid chromatographic 
column, thus presenting purified material for either MS or tandem MS/MS. Chromatography 
is important, since it enables the separation of closely related PLs including isobaric species 
(with the same m/z values) and isomers, and determine their MS behavior separately. For 
readers wishing to learn more about tandem MS of oxidized FA, 
prostaglandins/eicosanoids, PL and oxPL, and for libraries of MS/MS spectra, we direct the 
reader to reviews on this topic and to the LIPID MAPS database and resource(101-103).  In 
addition, LIPID MAPS have recently introduced new tools to aid the analysis of these lipids 
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including dedicated structure drawing tools and a computationally-generated database of 
oxidized PL chain composition masses.  
 
Summary 
Herein, we have summarized the state of the art relevant to the chemistry, biochemistry, 
cellular and clinical biology of new forms of oxPL that are generated by physiological 
enzymatic pathways.  It is now clear that individual cell types can generate large numbers of 
eoxPL, with the most abundant being HETE-PLs, and the full cellular complement of eoxPL 
in health and disease remains to be characterized in detail.  While the first discovered were 
mainly PE lipids, additional analogs are being found in human cells that include other PL 
classes such as phosphatidylinositols (PI). Much work remains to be done to fully 
understand the diversity of eoxPL as well as their detailed biological functions in innate and 
adaptive immunity.  The possibility of targeting the lipids and their biosynthetic enzymes for 
prevention of inflammatory/immune/thrombotic disease is now emerging.  
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Figure Legends 
 
 
Figure 1. Chemical mechanisms of lipid peroxidation.  Panel A. The underlying process 
of lipid peroxidation.  Panel B. A simplified diagram of non-enzymatic phospholipid 
oxidation.  
 
Figure 2. Direct oxidation of phospholipids (PL) by 12/15-LOX and Indirect oxidation 
of PL by the Land’s cycle to form eoxPL.  Panel A. Direct oxidation of membrane PLs 
This is achieved by hydrogen abstraction on the Sn2 fatty acid, usually arachidonic acid, 
followed by oxygen insertion and reduction, releasing a PL-hydroperoxide that is reduced by 
glutathione peroxidase 4 (GPX4) to form a PL-hydroxide.  Panel B. Indirect oxidation of PL.  
Phospholipase A2 (PLA2) hydrolysis of an Sn2 fatty acid releases substrate for LOX/COX 
oxidation, forming an oxylipin which is then  
Figure 3. eoxPL support the generation of a pro-thrombotic surface on platelets, 
facilitating haemostasis.  Activated platelets externalize aPL and eoxPL to form an 
electronegative surface that supports calcium-dependent binding and activation of 
coagulation factors, leading to thrombin formation.    
 
Figure 4. eoxPL expressed on the surface of resident macrophages facilitate 
clearance of apoptotic cells.  In this mechanism, MFG-E8 binds PS on apoptotic cells and 
macrophages, acting as a bridge to facilitate recognition and uptake by the macrophages 
themselves.  Conversely, this prevents uptake of apoptotic cell sby inflammatory monocytes 
that do not generate eoxPL.   
 
Figure 5. eoxPL formation is required for ferroptosis.  Although the detailed enzymology 
of how eoxPL support ferroptosis is not yet fully clear, the following has been proposed.  
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First, the formation of PL with long PUFA chains is facilitated by ACSL4. Then, oxidation of 
PE to form hydroperoxides is mediated by 15-LOX.  Last, iron-dependent lipid peroxidation 
during ferroptosis involves insufficiency and shutdown of anti-oxidative enzymes such as 
GPX4 as well as LOX-mediated peroxidation that at least partially involves 15-LOX.   
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Table 1. Free Radical Products that form as oxPL 
 
 
 
 
Monosubstituted  Polyoxygenated   Chain-Shortened 
Hydroperoxide  Dihydroperoxy   ω-aldehydes 
Hydroxy   Dihydroxy    ω-carboxyl 
Keto    Hydroxy, hydroperoxy  ω-aldehyde-γ-hydroxy 
Epoxy    Keto, hydroxy   ω-carboxy-γ-hydroxy 
Nitroalkanes   Hydrohydrins    ω-carboxy-γ-keto 
     Nitro,hydroxy    furan   
     Ozonides    butanoyl (alkane) 
     Isoprostanes    butenoyl (alkene) 
     F2-isoprostanes 
     E2/D2-isoprostanes 
     Epoxy-isoprostanes 
     Isothromboxanes 
     Isoleukotrienes 
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